Skip to main content
Journal cover image

Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients.

Publication ,  Journal Article
Hess, CN; Broderick, S; Piccini, JP; Alexander, KP; Newby, LK; Shaw, LK; Mahaffey, KW; Alexander, JH; Peterson, ED; Granger, CB; Lopes, RD
Published in: American heart journal
October 2012

Older patients with atrial fibrillation (AF) and coronary artery disease (CAD) face high risk of stroke and bleeding with antithrombotic therapy. Balancing safe and effective use of aspirin, clopidogrel, and warfarin in this population is important.From the Duke Databank for Cardiovascular Disease, we identified patients with AF ≥65 years old with angiographically confirmed CAD from 2000 to 2010. Antithrombotic use was described across age and Congestive heart failure, Hypertension, Age >75 years, Diabetes, prior Stroke/transient ischemic attack (CHADS(2)) stroke risk and Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) bleeding scores. Death and the composite of death, myocardial infarction, and stroke by antithrombotic strategy were reported.Of 2,122 patients ≥65 years old with AF and CAD, 477 (22.5%) were ≥80 years old; 1,133 (53.4%) had acute coronary syndromes. Overall rates of aspirin, clopidogrel, and warfarin use were 83.4%, 34.6%, and 38.9%, respectively. Compared with patients 65 to 79 years old, more patients ≥80 years old were at high stroke risk (CHADS(2) ≥2, 84.7% vs 57.8%) and high bleeding risk (ATRIA 5-10, 55.8% vs 23.3%). Warfarin use in both age groups increased with higher CHADS(2) scores and decreased with higher ATRIA scores. Of patients ≥80 years old with CHADS(2) ≥2, 150 (38.2%) received warfarin. Antithrombotic strategy was not associated with improved 1-year adjusted outcomes.Among older patients with AF and CAD, overall warfarin use was low. Patients ≥80 years old at highest stroke risk received warfarin in similar proportions to the overall cohort. Further investigation into optimizing antithrombotic strategies in this population is warranted.

Duke Scholars

Published In

American heart journal

DOI

EISSN

1097-6744

ISSN

0002-8703

Publication Date

October 2012

Volume

164

Issue

4

Start / End Page

607 / 615

Related Subject Headings

  • Warfarin
  • Treatment Outcome
  • Ticlopidine
  • Stroke
  • Risk Assessment
  • Male
  • Hypertension
  • Humans
  • Heart Failure
  • Fibrinolytic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hess, C. N., Broderick, S., Piccini, J. P., Alexander, K. P., Newby, L. K., Shaw, L. K., … Lopes, R. D. (2012). Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients. American Heart Journal, 164(4), 607–615. https://doi.org/10.1016/j.ahj.2012.07.004
Hess, Connie N., Samuel Broderick, Jonathan P. Piccini, Karen P. Alexander, L Kristin Newby, Linda K. Shaw, Kenneth W. Mahaffey, et al. “Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients.American Heart Journal 164, no. 4 (October 2012): 607–15. https://doi.org/10.1016/j.ahj.2012.07.004.
Hess CN, Broderick S, Piccini JP, Alexander KP, Newby LK, Shaw LK, et al. Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients. American heart journal. 2012 Oct;164(4):607–15.
Hess, Connie N., et al. “Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients.American Heart Journal, vol. 164, no. 4, Oct. 2012, pp. 607–15. Epmc, doi:10.1016/j.ahj.2012.07.004.
Hess CN, Broderick S, Piccini JP, Alexander KP, Newby LK, Shaw LK, Mahaffey KW, Alexander JH, Peterson ED, Granger CB, Lopes RD. Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients. American heart journal. 2012 Oct;164(4):607–615.
Journal cover image

Published In

American heart journal

DOI

EISSN

1097-6744

ISSN

0002-8703

Publication Date

October 2012

Volume

164

Issue

4

Start / End Page

607 / 615

Related Subject Headings

  • Warfarin
  • Treatment Outcome
  • Ticlopidine
  • Stroke
  • Risk Assessment
  • Male
  • Hypertension
  • Humans
  • Heart Failure
  • Fibrinolytic Agents